USANA Health Sciences, Inc. (NYSE:USNA) Director Sells $21,190.56 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Gilbert A. Fuller sold 674 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $31.44, for a total value of $21,190.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

USANA Health Sciences Stock Performance

Shares of USNA stock opened at $32.49 on Thursday. USANA Health Sciences, Inc. has a one year low of $27.71 and a one year high of $50.32. The company’s 50-day simple moving average is $32.86 and its 200-day simple moving average is $36.08. The stock has a market capitalization of $619.32 million, a price-to-earnings ratio of 11.48, a PEG ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The business had revenue of $213.61 million for the quarter, compared to analysts’ expectations of $208.82 million. As a group, research analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Hedge Funds Weigh In On USANA Health Sciences

Large investors have recently bought and sold shares of the business. Barclays PLC lifted its holdings in USANA Health Sciences by 111.9% in the third quarter. Barclays PLC now owns 27,737 shares of the company’s stock worth $1,052,000 after acquiring an additional 14,647 shares during the last quarter. Rhumbline Advisers increased its stake in shares of USANA Health Sciences by 39.8% in the fourth quarter. Rhumbline Advisers now owns 49,390 shares of the company’s stock valued at $1,773,000 after purchasing an additional 14,068 shares during the period. Principal Financial Group Inc. increased its stake in shares of USANA Health Sciences by 2.8% in the fourth quarter. Principal Financial Group Inc. now owns 53,603 shares of the company’s stock valued at $1,924,000 after purchasing an additional 1,480 shares during the period. Geode Capital Management LLC increased its stake in shares of USANA Health Sciences by 4.5% in the third quarter. Geode Capital Management LLC now owns 297,120 shares of the company’s stock valued at $11,269,000 after purchasing an additional 12,898 shares during the period. Finally, State Street Corp increased its stake in shares of USANA Health Sciences by 0.6% in the third quarter. State Street Corp now owns 435,164 shares of the company’s stock valued at $16,501,000 after purchasing an additional 2,782 shares during the period. Institutional investors own 54.25% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. DA Davidson lowered their target price on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. Finally, Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.